CEB-01 in Locally Resectable Pancreatic Cancer

The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the pancreatic cancer tumor, CEB 01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of pancreatic cancer after surgery, while keeping a tolerable toxicity profile. The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in patients with locally resectable pancreatic cancer

Trial Details

NCT ID

NCT06538857

Phase

PHASE2

Sponsor

CEBIOTEX

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Standard surgery
CEB-01

Locations (sample)

Barcelona, Catalonia, Spain|41.38879,2.15899
Madrid, Madrid, Spain|40.4165,-3.70256
Seville, Sevilla, Spain|37.38283,-5.97317
Valencia, Valencia, Spain|39.47391,-0.37966

Key Eligibility Criteria

Age ≥18 years.
Participants must have a diagnosis of:
Lesion/s of histologically or cytologically confirmed de novo carcinoma, adenocarcinoma or ductal adenocarcinoma of the pancreas with only locally …
Histopathological confirmation of the diagnosis can be done during surgery by means of intraoperative biopsy as per clinical practice.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →